"currently, 41 out of the 198 countries have legalized cannabis for medicinal use, while only 2 of 198 have legalized for recreational.
However, in the next 24 months, those numbers are set to double. Medicinal cannabis could (should) be legal in over 80 countries, whilst recreational is most probably doubled by the Netherlands and New Zealand at best.
The point is the size and potential.
Look for investor sentiment and capital to start slowly moving back to the biotechs and pharmaceutical companies looking to leverage the greatest healthcare disrupter of our time. We believe big money will flow into medical this year as investors start to understand just how long it might take for the recreational markets to truly find their footing."
I THINK ITS A GOOD YEAR TO BE IN BIOTECHS, NAMELY THIS ONE, LOOKING TO LEVERAGE THIS STAGE OF THE CYCLE AND PRODUCE VALUE:
- PROPRIETARY, BRANDED PRODUCTS (HOPE+AUTISM) - REVENUES - EXPANDED RESEARCH INTO NEW P2 AUTISM TRIALS - DERMATOLOGY AND OLD AGE CARE - CLINICAL VALIDATION (Potentially the worlds first clinically validated full spectrum Insomnia medication)
